U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Walton M, Wade R, Claxton L, et al. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Southampton (UK): NIHR Journals Library; 2020 Sep. (Health Technology Assessment, No. 24.48.)

Cover of Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation

Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.

Show details

Appendix 13Random-effects network meta-analysis results

TABLE 43

Random-effects NMA OS results of base-case NMA, including Biederman et al.39 in the ITT and per-protocol populations: adults with unresectable HCC who are ineligible for CTT

InterventionComparatorHR (95% CrI)
ITTPer protocol
SIR-SpheresSorafenib0.94 (0.68 to 1.26)1.13 (0.86 to 1.46)
SIR-SpheresLenvatinib0.92 (0.52 to 1.51)1.11 (0.66 to 1.74)
TheraSphereSIR-Spheres0.46 (0.19 to 0.94)0.42 (0.19 to 0.82)
TheraSphereSorafenib0.42 (0.18 to 0.83)0.48 (0.20 to 0.97)
TheraSphereLenvatinib0.41 (0.15 to 0.89)0.46 (0.17 to 1.02)
LenvatinibSorafenib1.07 (0.67 to 1.63)1.07 (0.70 to 1.58)
SD0.11 (0.004 to 0.352)0.13 (0.005 to 0.378)
DIC0.92.1
pD3.43.4

pD, number of parameters.

TABLE 44

Random-effects OS and PFS outcomes for all patients in the NMA ITT population: adults with unresectable HCC who are ineligible for CTT

InterventionComparatorHR (95% CrI), random effects
OSPFS
SIR-SpheresSorafenib0.97 (0.73 to 1.26)1.15 (0.89 to 1.45)
SIR-SpheresLenvatinib1.58 (0.40 to 4.21)1.12 (0.68 to 1.73)
LenvatinibSorafenib0.87 (0.23 to 2.33)1.07 (0.70 to 1.57)
SD0.11 (0.004 to 0.352)0.12 (0.005 to 0.367)
DIC–1.692.18
pD2.42.5

pD, number of parameters.

TABLE 45

Random-effects NMA of all adults with unresectable HCC who are ineligible for CTT, including studies Biederman et al.39 and Van Der Gucht et al.40

InterventionComparatorOS HR (95% CrI)
SIR-SpheresSorafenib1.15 (0.89 to 1.45)
SIR-SpheresLenvatinib1.11 (0.68 to 1.73)
TheraSphereSIR-Spheres0.50 (0.26 to 0.89)
TheraSphereSorafenib0.58 (0.29 to 1.06)
TheraSphereLenvatinib0.56 (0.24 to 1.13)
LenvatinibSorafenib1.07 (0.70 to 1.57)

TABLE 46

Results of random-effects base-case NMA, excluding the SIRveNIB study

InterventionComparatorOS HR (95% CrI)
ITT populationPer-protocol population
SIR-SpheresSorafenib1.16 (0.71 to 1.78)1.03 (0.63 to 1.61)
SIR-SpheresLenvatinib1.13 (0.55 to 2.09)1.02 (0.49 to 1.88)
LenvatinibSorafenib1.08 (0.65 to 1.71)1.08 (0.65 to 1.71)
SD0.15 (0.006 to 0.426)0.15 (0.006 to 0.426)
DIC0.921.1
pD2.02.0

pD, number of parameters.

Copyright © Queen’s Printer and Controller of HMSO 2020. This work was produced by Walton et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Bookshelf ID: NBK562654
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (3.2M)

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...